Table 2.
Outcomes and costs in the economic evaluation of Evushelda
| Organ transplant patients (N = 8325) | Autoimmune disease patients (N = 331,378) | Dialysis patients (N = 17,652) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| COVID-19 vaccine | Evusheld Policy 1b | Evusheld Policy 2c | COVID-19 vaccine | Evusheld Policy 1b | Evusheld Policy 2c | COVID-19 vaccine | Evusheld Policy 1b | Evusheld Policy 2c | |
| Outcomes (6 months, undiscounted) | |||||||||
| Number of COVID-19 infections | 377 | 67 | 67 | 10,494 | 1839 | 1839 | 1267 | 228 | 228 |
| Number of severe infections | 18 | 1 | 1 | 115 | 3 | 3 | 91 | 3 | 3 |
| Number of deaths from COVID-19 | 6 | 0.2 | 0.2 | 38 | 1 | 1 | 53 | 2 | 2 |
| QALYs | 3388 | 3389 | 3389 | 134,889 | 134,917 | 134,917 | 7174 | 7186 | 7186 |
| Cost (6 months, undiscounted) | |||||||||
| Total costs (THB) | 48,957,300 | 249,292,900 | 105,769,900 | 1,303,276,900 | 9,833,612,700 | 4,120,656,000 | 198,701,900 | 544,177,000 | 239,856,500 |
| Cost-effectiveness (vs COVID-19 vaccine as a reference) | |||||||||
| Incremental cost (THB) | Reference | 200,335,600 | 56,812,600 | Reference | 8,530,335,800 | 2,817,379,100 | Reference | 345,475,100 | 41,154,600 |
| Incremental QALYs (lifetime, discounted) | 80 | 80 | 558 | 558 | 753 | 753 | |||
| ICER (THB/QALY) | 2,489,600 | 706,000 | 15,295,000 | 5,051,500 | 458,900 | 54,700 | |||
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, THB Thai Baht
aThe numbers presented in the table were rounded to the nearest whole number
bEvusheld Policy 1 refers to the provision of Evusheld to all patients at least 2–4 weeks after the COVID-19 vaccine
cEvusheld Policy 2 refers to the provision of Evusheld to individuals who had low levels of protective immunity at least 2-4 weeks after the COVID-19 vaccine